| 吴菲,眭玉霞,魏晓霞,等.亚胺培南 /西司他丁与美罗培南在中重度肺部感染人群中的成本效果分析[J].安徽医药,2021,25(6):1263-1266. |
| 亚胺培南 /西司他丁与美罗培南在中重度肺部感染人群中的成本效果分析 |
| Cost-effectiveness analysis of imipenem/cilastatin versus meropenem in treating patients with moderate to severe pulmonary infection |
| |
| DOI：10.3969/j.issn.1009-6469.2021.06.050 |
| 中文关键词: 呼吸道感染 亚胺培南 /西司他丁 美罗培南 药物经济学 成本及成本分析 |
| 英文关键词: Respiratory tract infections Imipenem/cilastatin Meropenem Pharmacoeconomic Costs and cost analysis |
| 基金项目: |
|
| 摘要点击次数: 1448 |
| 全文下载次数: 450 |
| 中文摘要: |
| 目的探讨亚胺培南 /西司他丁和美罗培南治疗中重度肺部感染人群的药物经济学评价。方法通过 “PASS合理用药监测系统”收集福建省立医院 2016年 1月至 2019年 6月 55例临床诊断为肺部感染且使用亚胺培南 /西司他丁(亚西组)或美罗培南(美罗组)抗感染治疗的病人的病历资料，比较两组病人治疗前后炎症指标及临床疗效，观察不良反应发生情况，并采用成本效果分析法评价两组方案。结果亚西组与美罗组总有效率比较［23例( 92.00%)比 28例( 93.33%)］差异无统计学意义(P>0.05)。除去治疗无效的病人，两组总有效病人经治疗后白细胞计数、中性比、降钙素原和 C反应蛋白显，著低于治疗前，差异有统计学意义( P<0.05)；上述指标组间比较，差异无统计学意义( P>0.05)。亚西组与美罗组药品不良反应发生率分别为且8.00%、3.33%，差异无统计学意义( P>0.05)。成本效果分析显示，亚西组病人的成本高于美罗组［( 4 298.89±2 161.21)元比( 3 121.60±1 292.81)元， P<0.05］。结论两组治疗中重度肺部感染的有效性、安全性相当；但经济性方面，美罗培南优于亚胺培南/西司他丁。 |
| 英文摘要: |
| Objective To investigate the cost-effectiveness of imipenem/cilastatin and meropenem in the treatment of patients with moderate to severe pulmonary infection.Methods Clinical data of 55 patients with moderate to severe pulmonary infections receivingimipenem/cilastatin and meropenem were collected by "PASS rational drug use monitoring system" in Fujian Provincial Hospital fromJanuary 2016 to June 2019. Inflammatory markers and clinical efficacy were compared between 2 groups before and after treatment.The occurrence of adverse drug reaction (ADR) was observed in 2 groups, and the plan of the two groups was conducted by cost-effectiveness analysis.Results There was no statistical significance in total effective rates between 2 groups (P>0.05). In addition to patients who were not responding to treatment,white blood cell count, neutrophil percentage, procalcitonin and c-reactive protein were lower than before treatment, with statistical significance (P<0.05). But there was no statistical significance in these indexes between 2 groups (P>0.05). The rates of adverse reactions in two groups were 8.00% and 3.33% respectively with no statistical significance (P> 0.05). Cost-effectiveness analysis showed that the cost of imipenem/ cilastatin group was higher than that of meropenem group [(4298.89±2 161.21) yuan vs. (3 121.60±1 292.81) yuan, P<0.05].Conclusion The effectiveness and safety of imipenem/cilastatin aresimilar to meropenem. Meropenem is superior to imipenem/cilastatin in terms of economy. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
